论文部分内容阅读
[目的]进一步证实经验方剂益气软肝方(PGSL)抗肝纤维化的作用。[方法]SD大鼠53只,随机分成正常对照组(8只)、肝纤维化组(15只)、保护组(15只)和治疗组(15只)。用人清蛋白建立大鼠免疫性肝纤维化模型;生化全自动分析仪测定血清转氨酶等;放免法测定血清透明质酸(HA)和层黏连蛋白(LN);肝组织羟脯氨酸(HYP)测定参照郑少雄方法;ELISA法测定血清转化生长因子β1(TGF-β1)的表达;苏木精-伊红、嗜银和VG染色分别观察肝纤维化程度、分布和成纤维细胞、Ⅰ型和Ⅲ型胶原增生程度,免疫组化法检测α-平滑肌肌动蛋白(α-SMA)在肝组织中的表达;扫描电镜观察肝细胞,透射电镜观察汇管区、纤维间隔以外窦周梭形细胞的变化。[结果]PGSL可降低死亡率,降低转氨酶、HA、LN、HYP、成纤维细胞、Ⅰ型及Ⅲ型胶原增生程度、TGF-β1,减少激活肝星状细胞的数目及抑制炎细胞浸润。[结论]PGSL可降低肝纤维化大鼠的死亡率,保护肝细胞,延缓和抑制肝纤维化。
[Objective] To further confirm the anti-fibrotic effect of experience prescription qiqiganganfang (PGSL). [Methods] A total of 53 SD rats were randomly divided into normal control group (8), liver fibrosis group (15), protection group (15) and treatment group (15). Human albumin was used to establish immune hepatic fibrosis model; biochemical automatic analyzer was used to determine serum transaminase; radioimmunoassay was used to determine serum HA and laminin (LN); liver tissue hydroxyproline (HYP) Determine the reference Zheng Shaoxiong method; ELISA determination of serum transforming growth factor-β1 (TGF-β1) expression; hematoxylin-eosin, silver-free and VG staining were observed liver fibrosis degree, distribution and fibroblasts, type I and The degree of type III collagen proliferation was measured by immunohistochemistry to detect the expression of α-smooth muscle actin (α-SMA) in liver tissue. The hepatocytes were observed by scanning electron microscope. Transmission electron microscope was used to observe the sinusoidal spindle cells in the portal area and fibrous septum. Variety. [Results] PGSL can reduce the mortality, reduce the transaminase, HA, LN, HYP, fibroblasts, type I and type III collagen proliferation, TGF-β1, reduce the number of activated hepatic stellate cells and inhibit inflammatory cell infiltration. [Conclusion] PGSL can reduce the mortality of hepatic fibrosis rats, protect hepatocytes, delay and inhibit hepatic fibrosis.